MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN

被引:62
|
作者
Zhu Deng-Yan [1 ]
Li Xiang-Nan [1 ]
Yu, Qi [1 ]
Liu Dong-Lei [1 ]
Yang, Yang [1 ]
Jia, Zhao [1 ]
Zhang Chun-Yang [1 ]
Kai, Wu [1 ]
Song, Zhao [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China
关键词
MiR-454; Non-small cell lung cancer; PTEN; Prognosis; Proliferation; Apoptosis; PROLIFERATION; EXPRESSION; ONCOGENE; INVASION;
D O I
10.1016/j.biopha.2016.03.029
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: MicroRNA-454 has been proven dysregulated in some human malignancies and correlated with tumor progression. However, its expression and function in non-small cell lung cancer (NSCLC) is still unclear. Thus, the aim of this study was to explore the effects of miR-454 in NSCLC tumorigenesis and development. Methods: Using quantitative RT-PCR, we detected miR-454 expression in NSCLC cell lines and primary tumor tissues. The association of miR-454 expression with clinicopathological factors and prognosis was also analyzed. Then, the effects of miR-454 on the biological behavior of NSCLC cells were investigated. At last, the potential regulatory function of miR-454 on PTEN expression was confirmed. Results: miR-454 was found to be up-regulated in NSCLC tissues and cell lines. High miR-454 expression was closely correlated with lymph node metastasis, advanced TNM stage, and shorter overall survival. Multivariate regression analysis corroborated that miR-454 overexpression was an independent unfavourable prognostic factor for patients with NSCLC. Down-regulation of miR-454 could significantly reduce NSCLC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while up-regulation of miR-454 showed opposite effects. Further, PTEN was confirmed as a direct target of miR-454 by using Luciferase Reporter Assay. Conclusions: These findings indicate that miR-454 may act as an oncogene in NSCLC and would serve as a potential therapy target for this disease. a 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 50 条
  • [41] High level of BRD4 promotes non-small cell lung cancer progression
    Liao, Yun-Fei
    Wu, Yong-Bing
    Long, Xiang
    Zhu, Shu-Qiang
    Jin, Chun
    Xu, Jian-Jun
    Ding, Jian-Yong
    ONCOTARGET, 2016, 7 (08) : 9492 - 9501
  • [42] miR-25 promotes invasion of human non-small cell lung cancer via CDH1
    Liu, Bing
    Sun, Xuerong
    BIOENGINEERED, 2019, 10 (01) : 271 - 281
  • [43] TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT
    Sun, Haohui
    Li, Xiaodi
    Long, Qian
    Wang, Xiaonan
    Zhu, Wancui
    Chen, Enni
    Zhou, Wenhao
    Yang, Han
    Huang, Chuyang
    Deng, Wuguo
    Chen, Miao
    ISCIENCE, 2024, 27 (06)
  • [44] Other compounds and targets in non-small cell lung cancer
    Villaflor, V
    Bonomi, P
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S30 - S36
  • [45] Molecular therapeutic targets in non-small cell lung cancer
    Sankar, Kamya
    Gadgeel, Shirish M.
    Qin, Angel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (08) : 647 - 661
  • [46] Novel Therapeutic Targets in Non-small Cell Lung Cancer
    Janku, Filip
    Garrido-Laguna, Ignacio
    Petruzelka, Lubos B.
    Stewart, David J.
    Kurzrock, Razelle
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1601 - 1612
  • [47] Novel Targets in Advanced Non-Small Cell Lung Cancer
    Liu, Stephen, V
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 426 - 429
  • [48] NOVEL TARGETS AND THERAPIES IN NON-SMALL CELL LUNG CANCER
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S93 - S93
  • [49] Novel therapeutic targets in non-small cell lung cancer
    Alamgeer, Muhammad
    Ganju, Vinod
    Watkins, D. Neil
    CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 394 - 401
  • [50] miR-671-3p is downregulated in non-small cell lung cancer and inhibits cancer progression by directly targeting CCND2
    Yao, Yuanshan
    Zhou, Yinjie
    Fu, Xiaojun
    MOLECULAR MEDICINE REPORTS, 2019, 19 (03) : 2407 - 2412